Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 18,411 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Female Clear all
Completed Not applicable Interventional

Perioperative Outcome Risk Assessment With Computer Learning Enhancement

NCT05042804
View directory record Official record
Conditions
Morality, Acute Kidney Injury
Interventions
Machine learning models predicting postoperative death and acute kidney injury
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
5,114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 4 Interventional

TESTO: Testosterone Effects on Short-Term Outcomes in Infants With XXY

NCT03325647
View directory record Official record
Conditions
Klinefelter Syndrome
Interventions
Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution, Placebo injectable saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 90 Days · Male only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/II Trial of RAD001 Plus Nexavar in Patients With Kidney Cancer

NCT00448149
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
RAD001, Sorafenib
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 17, 2016 · Synced Oct 30, 2026, 10:37 PM EDT
Active, not recruiting Phase 3 Interventional

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06500455
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
262
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Recruiting No phase listed Observational

Polycystic Kidney Disease Data Repository

NCT00792155
View directory record Official record
Conditions
Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 30, 2026, 10:37 PM EDT
Completed No phase listed Observational

Impact of Drug Therapy and Co-Morbidities on the Development of Renal Impairment in HIV-Infected Patients

NCT00551655
View directory record Official record
Conditions
Human Immunodeficiency Viruses, Kidney Failure, HIV Infections
Interventions
Not listed
Lead sponsor
AIDS Arms Inc.
Other
Eligibility
18 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing Contraception Utilization Among Women Prescribed Teratogenic Medications

NCT01624155
View directory record Official record
Conditions
Teratogenesis
Interventions
Education
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 2Phase 3 Interventional

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

NCT00035334
View directory record Official record
Conditions
Secondary (AA) Amyloidosis, Rheumatoid Arthritis, Nephrotic Syndrome, Familial Mediterranean Syndrome, Kidney Diseases, Gastrointestinal Diseases
Interventions
NC-503 (Anti-amyloidotic (AA) Agent)
Drug
Lead sponsor
Bellus Health Inc. - a GSK company
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
4
States / cities
Indianapolis, Indiana • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2006 · Synced Oct 30, 2026, 10:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

NCT06434363
View directory record Official record
Conditions
Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis
Interventions
Tafasitamab, Fludarabine phosphate, Cyclophosphamide, Tafasitamab and NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Single-incision Sling vs Urethral Bulking During Prolapse Surgery for Occult Stress Incontinence

NCT05210738
View directory record Official record
Conditions
Stress Incontinence, Female
Interventions
Single incision sling, Bulkamid bulking agent
Device · Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years to 85 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 30, 2026, 10:37 PM EDT
Not yet recruiting Phase 2 Interventional

Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer

NCT07820358
View directory record Official record
Conditions
Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial Cancer Stage I, Endometrial Cancer, Fertility-Sparing Treatment (FST), Obesity & Overweight
Interventions
Semaglutide (Wegovy) weekly injection, LNG-IUD (Progestin), Structured Weight Loss Program
Drug · Device · Behavioral
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
4
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Not listed Phase 4 Interventional

Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease

NCT02364648
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
MitoQ, Placebo
Dietary Supplement
Lead sponsor
University of Delaware
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 25, 2019 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Not applicable Interventional

Parathyroid Hormone Levels in Relation to the Phosphorus Content of Meals

NCT00018135
View directory record Official record
Conditions
Renal Failure
Interventions
calcium acetate, aluminum hydroxide, Sevelamer
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 30, 2026, 10:37 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Advancing Stillbirth Prevention Through Innovative Risk Evaluation (ASPIRE) Clinical Study

NCT07669935
View directory record Official record
Conditions
GDM, Preterm Preeclampsia, Preeclampsia, Fetal Growth Restriction (FGR), Pregnancy Complications
Interventions
None (this is an observational study with no intervention)
Other
Lead sponsor
Medicines360
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
5,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Baton Rouge, Louisiana • Potsdam, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Terminated Not applicable Interventional Results available

COVID-19 Testing in Underserved and Vulnerable Populations

NCT05315908
View directory record Official record
Conditions
Heart Failure, Coronary Artery Disease, Cancer, Chronic Kidney Diseases, COPD, Obesity, Sickle Cell Disease, Diabetes Mellitus, Type 2
Interventions
Community outreach method
Other
Lead sponsor
Jesse Nodora
Other
Eligibility
21 Years and older
Enrollment
9,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 2 Interventional

Biobehavioral Intervention in Gynecologic Oncology Patients

NCT02454036
View directory record Official record
Conditions
Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vulva
Interventions
BBI intervention
Behavioral
Lead sponsor
Rachel Miller
Other
Eligibility
21 Years to 80 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

BMS 247550 to Treat Kidney Cancer

NCT00030992
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
BMS-247550, Ranitidine, Diphenhydramine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2012 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

NCT00471536
View directory record Official record
Conditions
Distal Urethral Cancer, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer
Interventions
pazopanib hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
7
States / cities
Jacksonville, Florida • Baltimore, Maryland • Detroit, Michigan + 4 more
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Oct 30, 2026, 10:37 PM EDT
Completed No phase listed Observational

Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole

NCT00316836
View directory record Official record
Conditions
Breast Cancer
Interventions
mammography
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
311
States / cities
Fairbanks, Alaska • Scottsdale, Arizona • Fort Smith, Arkansas + 222 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 30, 2026, 10:37 PM EDT
Suspended Phase 1 Interventional

A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer

NCT02093871
View directory record Official record
Conditions
Ovarian Cancer
Interventions
ThermalCore Hyperthermia System
Device
Lead sponsor
ThermalCore Inc
Industry
Eligibility
18 Years to 69 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
San Jose, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 30, 2026, 10:37 PM EDT
Completed No phase listed Observational

Pregnancy Outcomes After Uterine Cavity Expansion

NCT03218878
View directory record Official record
Conditions
Miscarriage, Uterus Abnormal, Infertility
Interventions
Not listed
Lead sponsor
Reproductive Medicine Associates of New Jersey
Other
Eligibility
18 Years and older · Female only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Basking Ridge, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of a Podcast-based Body Image Intervention Among Millennial Women

NCT07113678
View directory record Official record
Conditions
Body Image
Interventions
Body confidence podcast episode and supplementary exercises in a journal, Body confidence podcast episode, Non-body image-related podcast episode
Behavioral
Lead sponsor
University of the West of England
Other
Eligibility
29 Years to 44 Years · Female only
Enrollment
1,351 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 30, 2026, 10:37 PM EDT
Completed Phase 2 Interventional Results available

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

NCT01010126
View directory record Official record
Conditions
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma, Lung Carcinoid Tumor, Malignant Pancreatic Gastrinoma, Malignant Pancreatic Glucagonoma, Malignant Pancreatic Insulinoma, Malignant Pancreatic Somatostatinoma, Metastatic Digestive System Neuroendocrine Tumor G1, Ovarian Carcinosarcoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Pancreatic Alpha Cell Adenoma, Pancreatic Beta Cell Adenoma, Pancreatic Delta Cell Adenoma, Pancreatic G-Cell Adenoma, Pancreatic Polypeptide Tumor, Recurrent Adult Liver Carcinoma, Recurrent Digestive System Neuroendocrine Tumor G1, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Neuroendocrine Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Regional Digestive System Neuroendocrine Tumor G1, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIA Uterine Corpus Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIC Uterine Corpus Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Uterine Corpus Cancer, Stage IVB Uterine Corpus Cancer, Uterine Carcinosarcoma
Interventions
Bevacizumab, Temsirolimus
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
57
States / cities
Scottsdale, Arizona • Beverly Hills, California • Duarte, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2019 · Synced Oct 30, 2026, 10:37 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Sleep-wake Changes of Luteinizing Hormone Frequency in Pubertal Girls With and Without High Testosterone

NCT00930007
View directory record Official record
Conditions
Hyperandrogenism
Interventions
Blood sampling
Other
Lead sponsor
University of Virginia
Other
Eligibility
8 Years to 15 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 30, 2026, 10:37 PM EDT